ClinicalTrials.Veeva

Menu

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

M.D. Anderson Cancer Center logo

M.D. Anderson Cancer Center

Status

Enrolling

Conditions

Financial Toxicity
Bone Sarcomas

Treatments

Other: data collection

Study type

Observational

Funder types

Other

Identifiers

NCT07215611
2024-1156
NCI-2025-07460 (Other Identifier)

Details and patient eligibility

About

To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about the effects of financial stress on participants quality of life.

Full description

Measure the prevalence of financial toxicity and the severity of it in orthopaedic oncology patients undergoing surgical intervention using an objective, validated instrument. Secondary objectives include identifying socioeconomic and demographic risk factors for financial toxicity and evaluating clinicopathologic characteristics that may worsen financial stress in this population.

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Participants who are seen preoperatively at our institution before surgery for primary malignant bone tumor or primary malignant soft tissue tumor will be identified.
  • Adult orthopedic oncology patients. Stratified by diagnosis of primary malignant bone tumor and primary malignant soft tissue tumor.

Exclusion Criteria

• Non-English subjects will not be recruited. Subjects are required to be able to read/write in English.

Trial contacts and locations

1

Loading...

Central trial contact

Shalin S Patel, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems